Figure 1

ACM from viscerally obese EAC patients induces mitochondrial dysfunction. OE33 cells were treated with ACM from non-obese (n = 5) and obese (n = 5) EAC patients for 24 h and mitochondrial function was assessed. Data are presented as the mean ± SEM. Analysis was performed by two-tailed Student’s t-test. (A) Mitochondrial mass was significantly increased in cells treated with ACM from obese patients, when compared to cells treated with ACM from non-obese patients and untreated controls, **p < 0.01. (B) Mitochondrial membrane potential was significantly increased in cells treated with ACM from obese patients, when compared to cells treated with ACM from non-obese patients, ***p < 0.001. (C) ROS levels were significantly reduced in cells treated with ACM from both non-obese and obese EAC patients, when compared to untreated controls, *p < 0.05, **p < 0.01. Mitochondrial Mass (D) and mitochondrial membrane potential (E) was significantly associated with visceral fat area. Analysis was performed using linear regression.